Haemonetics Corporation Haemonetics Corporation

Haemonetics Corporation

HAE

Rang in aandelen #3263
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Aandeelprijs
$118.50
Laatst gesynchroniseerd: 2026-10-19
Marktkapitalisatie
$5.39B
Verandering (1 dag)
0.01%
Verandering (1 jaar)
133.68%
Land
US
Handel Haemonetics Corporation (HAE)

Categorie

Healthcare
Winst voor Haemonetics Corporation (HAE)
Winst in Jun 2026 TTM: $130.44M
Volgens de meest recente financiële verslagen van Haemonetics Corporation bedraagt de huidige winst van het bedrijf $130.44M. In 2024 behaalde het bedrijf een winst van $151.87M, een stijging ten opzichte van de winst van 2023, die $141.40M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Haemonetics Corporation van 2000 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $130.44M -38.49%
2025 $212.07M 39.64%
2024 $151.87M 7.40%
2023 $141.40M 122.23%
2022 $63.63M -12.73%
2021 $72.91M -16.34%
2020 $87.15M 18.36%
2019 $73.63M 23.48%
2018 $59.63M -317.03%
2017 $-27.48M -48.56%
2016 $-53.42M -271.40%
2015 $31.17M -14.38%
2014 $36.40M -27.05%
2013 $49.90M -44.25%
2012 $89.50M -18.70%
2011 $110.08M 35.45%
2010 $81.27M -4.39%
2009 $85.00M 9.96%
2008 $77.30M 6.87%
2007 $72.34M -32.32%
2006 $106.88M 78.61%
2005 $59.84M 30.62%
2004 $45.81M 18.66%
2003 $38.61M 0.26%
2002 $38.51M 122.24%
2001 $17.33M -36.59%
2000 $27.33M 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$7.51B 5,658.42%
US
$5.56B 4,164.96%
IE
$5.15B 3,846.79%
US
$3.86B 2,860.10%
US
- -
DE